Aktienanalyse zu Co-Diagnostics Inc (CODX)CODXCo-Diagnostics Inc

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Co-Diagnostics Inc. is not a good buy right now due to its extremely low RSI of 10.186, indicating oversold conditions, and a staggering year-to-date change of -95.59%. The company is facing significant financial challenges, including a net loss of $9.14 million in Q1 2026, and a gross margin of -48.76% in Q2 2026, which raises concerns about its profitability and operational efficiency. The primary risk is its current price near the 52-week low of $0.24, which could lead to further declines if market conditions do not improve.